ClinicalTrials.gg
RecruitingNCT06956950Mgso4Updated May 11, 2025

Magnesium Sulfate in Addition to Bupivacaine in Ultrasound-guided Transmuscular Quadratus Lumborum Block for Post-Operative Analgesia After Total Hip Arthroplasty

A Phase 2/3 interventional study of Bupivacaine + Magnesium sulfate and Bupivacaine + saline in Pain Score Reduction, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-11.

Sponsored by Tanta University · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 146 studies testing bupivacaine in Pain — 19 open to participants now, 19 under way, 3 of them phase 3. Bupivacaine · Pain.

Planned enrollment
63rd of 146
70 · median 63
Started
2025
with 5 others
Phase 2/3
5 of 146
2 open now
Primary completion
2025-10
later than 5 of 18 live
Registered
136th of 146
by date

Among the 146 studies testing bupivacaine in Pain, this one is the 63rd largest by planned enrollment, is one of 6 that started in 2025, is one of 5 in phase 2/3, reaches primary completion later than 5 of the 18 other live ones, and was the 136th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

19 of the 146 studies testing bupivacaine in Pain are open now, in 5 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies testing bupivacaine in Pain, or all of them as a file.
02

Study summary

The aim of this clinical trial is to evaluate the efficacy of adding magnesium sulfate to bupivacaine in ultrasound-guided transmuscular quadratus lumborum block for postoperative analgesia in adult patients underdoing hip arthroplasty. The main questions it aims to answer are:

  • Does Magnesium sulphate lower Pain score (VAS) postoperatively.
  • Does Magnesium sulphate lowerTotal opioid consumption postoperatively. and What side effects do participants have when taking Magnesium sulphate? Researchers will compare Magnesium sulphate to a placebo (a look-alike substance that contains no drug) to see if Magnesium sulphate works to lower pain score.

Participants will:

  • Take with have ultrasound-guided transmuscular quadratus lumborum block after surgery using bupivacaine with Magnesium sulphate or with placebo
  • Followed up 48 hours postoperatively to monitor pain score or any reported side effect.
Read the detailed description

The quadratus lumborum block (QLB) is an abdominal wall fascial block plane block described for providing perioperative analgesia for abdominal, hip and lower limb surgeries . Opioid-sparing analgesic treatments for hip arthroplasty such as lumbar plexus and femoral nerve blocks, are effective but they carry a high risk of undesirable lower limb motor or muscle weakness. Fascia iliaca block, on the other hand, does not consistently provide adequate pain relief. Quadratus lumborum (QL) block is a relatively new truncal regional block technique that provides effective pain control after upper and lower abdominal surgeries. ersalis fascia laterally. The anterior QL block was also classified as transmuscular approach (in between QL and PM muscles) in earlier studies . Local anesthetic injected between the QL muscle and anterior layer of the thoracolumbar fascia can potentially spread to the thoracic paravertebral (PVB) space.

Magnesium plays an important role in the physiological function of the human body. A large number of studies have reported the safetyand effectiveness of adding magnesium sulfate in various regional anesthesia techniques . Therefore, this prospective randomized controlled study to compare the analgesic efficacy of combining magnesium sulfate with bupivacaine in QLB.

03

Conditions studied

  • Pain Score Reduction

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • American Society of Anesthesiology (ASA) class I-III
  • Undergoing hip arthroplasty .

Exclusion criteria

Exclusion Criteria:

  • Patient refusal.
  • (BMI) > 40 Kg/m2.
  • Allergy to local anesthetics or magnesium sulphate.
  • coexisting coagulopathy.
  • Local infection at puncture site.
  • Severe renal impairment ( \< 30 ml/min)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    bupivacaine /MgSo4

    patients will receive ipsilateral single-shot of ultrasound-guided transmuscular quadratus lumborum block using bupivacaine plus MgSo4 after surgery

    Drug: Bupivacaine + Magnesium sulfate

  • Active comparator
    bupivacaine/saline

    patients will receive ipsilateral single-shot of ultrasound-guided transmuscular quadratus lumborum block using bupivacaine plus saline after surgery

    Drug: Bupivacaine + saline

Interventions

  • DrugBupivacaine + Magnesium sulfate

    Drug pages: BupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Magnesium SulfateStudies of Magnesium SulfateMagnesium Sulfate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ultrasound-guided transmuscular quadratus lumborum block using 25 ml of 0.25% bupivacaine + 5 ml 10% magnesium sulfate

  • DrugBupivacaine + saline

    ultrasound-guided transmuscular quadratus lumborum block using 25 ml of 0.25% bupivacaine + 5 ml normal saline

06

What researchers measure

Primary outcomes

  1. postopeative pain Score

    The degree of pain will be assessed after surgery by Visual Analogue Score (score for the severity of pain in the range 0-10, where 0 = no pain and 10 = severe pain) at 6 , 12 , 24 , 48 hours postoperatively.

    Time frame: 48 hours postoperatively

Secondary outcomes

  1. Total opioid consumption

    total morphine consumption after surgery

    Time frame: 48 hours postoperatively

  2. Time to first rescue analgsic request

    Time frame: 48 hours postoperatively

07

Study locations

1 of 1 sites recruiting
  • Faculty of medicine
    Tanta, El-Gharbia 31527, Egypt
    Recruiting
    • Mohammed Hussain Mahmoud, professor · Contacttanta_unv@unv.tanta.edu.eg · +20403317236
    • Mostafa Mohammad Abdelsattar Elbagoury, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Oct 2025, 5 months later.

Of 35 non-industry phase 2/3 interventional studies under Pain, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 5 months is below that.

Counting every sponsor, half of 41 studies reached it within 20 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2025
First posted
May 4, 2025
StartEst.
May 2025
Primary completionEst.
Oct 9, 2025
CompletionEst.
Nov 2025
Last update
May 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06956950
Lead sponsor
Tanta University
Responsible party
Mostafa Mohammad Abdelsattar Elbagoury (Lecturer of anesthesia, surgical ICU and pain medicine, Tanta University) — Principal investigator
First posted
May 4, 2025
Start date
May 2025 (estimated)
Primary completion
Oct 9, 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
May 11, 2025

Study contacts

Mostafa Mohammad Abdelsattar Elbagoury, MD
Contact
mostafa.elbagoury@med.tanta.edu.eg
+201116297741
Dina Abdalla Elesawy Amer, MD
Contact
denaa_abdallah@yahoo.com
+201066376552
Mostafa Mohammad Abdelsattar Elbagoury, MD
principal investigator · lecturer of anesthesia and surgical ICU and pain medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Magnesium Sulfate

Start the discussion